Literature DB >> 2073905

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

E Pérez-Trallero, J M Garcia-Arenzana, J A Jimenez, A Peris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2073905     DOI： 10.1007/BF01967510

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  4 in total

1.  Penetration of ciprofloxacin into bronchial secretions.

Authors:  E Bergogne-Bérézin; G Berthelot; P Even; M Stern; P Reynaud
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

2.  Clinical use of the quinolones.

Authors:  H C Neu
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

3.  In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital.

Authors:  G Cornaglia; R Pompei; B Dainelli; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  In vitro activity of ciprofloxacin against gram-positive cocci.

Authors:  A L Barry; R N Jones
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965
  4 in total
  24 in total

1.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 2.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

3.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.

Authors:  H F Chambers; Q Xiang; L L Chow; C Hackbarth
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; K C Kugler; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 6.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Authors:  M Trautmann; M Ruhnke; K Borner; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

9.  In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.

Authors:  C E Thorburn; S J Knott; D I Edwards
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.